How EU Regulation Shifts Are Shaping Cibus’ Biofragrance Revenue in Q2 2025
Europe’s policy pivot on gene-edited plants is beginning to reshape commercial timelines for agricultural biotech. For Cibus, those changes are landing at an opportune moment, giving its fermentation-based fragrance program a clearer path to market. The result: Biofragrance Revenue looks better supported in Q2 2025 and positioned for steadier growth over the next few quarters.
Continue Reading on Meyka
This article is available in full on our main platform. Get access to complete analysis, stock insights, and more.
Read Full Article →
